|
Nexia Biotechnologies Announces Completion of Sale of All Assets Associated with Protexia(R) Monday March 14, 5:52 pm ET MONTREAL, March 14 /CNW Telbec/ - Nexia Biotechnologies Inc. (TSX: NXB - News) today announced completion of the sale of substantially all of its operations and assets related to Protexia(R) (recombinant human butyrylcholinesterase) to a wholly-owned subsidiary of PharmAthene, Inc. ("PharmAthene"), a privately held biotechnology company focused on the development of biodefense therapeutics, based in Annapolis, Maryland. Consequently, the distribution of $0.72 per share, resulting from the reduction of the stated capital of the issued and outstanding shares of Nexia approved by the shareholders on March 7, 2005, will be paid to shareholders of record on the close of business on March 23, 2005. http://www.newswire.ca/en/releases/orgDisplay.cgi?okey=35334 For further information Bill Garriock, President & CEO, Dejan Ristic, Acting CFO, Nexia Biotechnologies Inc., (450) 424-8922 |
|
| aus der Diskussion: | Nexia Biotech- große Zukunftsaussichten |
| Autor (Datum des Eintrages): | Bombenleger (15.03.05 13:03:44) |
| Beitrag: | 32 von 43 (ID:16096236) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |